• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

Professional Introduction to Compound with CAS No 1219803-20-9 and Product Name 4-PIPERIDINE-D9-CARBOXAMIDE

Compound with the CAS number 1219803-20-9 and the product name 4-PIPERIDINE-D9-CARBOXAMIDE represents a significant advancement in the field of pharmaceutical chemistry. This deuterated derivative of piperidine carboxamide has garnered considerable attention due to its unique structural properties and potential applications in drug development. The introduction of deuterium atoms in the molecule not only enhances its stability but also modifies its metabolic pathways, making it an attractive candidate for use in metabolic labeling studies and as a tool compound in biochemical research.

The 4-PIPERIDINE-D9-CARBOXAMIDE molecule is characterized by a piperidine ring substituted with a carboxamide group, where the carbon atoms at specific positions are replaced with deuterium isotopes. This modification is strategically designed to improve the compound's resistance to degradation by metabolic enzymes, thereby extending its half-life in biological systems. Such properties are particularly valuable in the context of positron emission tomography (PET) imaging probes, where longer-lasting signals can lead to more accurate diagnostic results.

Recent research has highlighted the utility of 4-PIPERIDINE-D9-CARBOXAMIDE in studying enzyme kinetics and substrate specificity. The deuterated version of the compound allows researchers to differentiate between natural and labeled substrates, providing insights into enzymatic processes that would be otherwise obscured. This capability is especially useful in the development of enzyme inhibitors, where understanding the interaction between the inhibitor and the target enzyme is critical.

In addition to its applications in biochemical research, 4-PIPERIDINE-D9-CARBOXAMIDE has shown promise in the field of drug discovery. The structural integrity provided by deuterium labeling can enhance the pharmacokinetic properties of drug candidates, potentially leading to more effective therapeutic agents. Studies have demonstrated that deuterated drugs often exhibit improved bioavailability and reduced susceptibility to metabolic pathways that lead to drug degradation. This has opened up new avenues for developing next-generation pharmaceuticals with enhanced efficacy and reduced side effects.

The synthesis of 4-PIPERIDINE-D9-CARBOXAMIDE involves sophisticated organic chemistry techniques, including multi-step reactions and precise isotopic labeling. The process requires careful optimization to ensure high yield and purity, which are essential for pharmaceutical applications. Advanced spectroscopic methods such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) are employed to verify the structural integrity of the compound at each stage of synthesis.

One of the most compelling aspects of 4-PIPERIDINE-D9-CARBOXAMIDE is its potential role in metabolic studies. By incorporating deuterium atoms into biological pathways, researchers can track metabolic fluxes with greater precision. This approach has been particularly useful in understanding how drugs are processed within the body, providing valuable data for optimizing dosages and delivery methods. Furthermore, such studies can help identify new targets for therapeutic intervention by revealing previously unknown metabolic pathways.

The application of 4-PIPERIDINE-D9-CARBOXAMIDE extends beyond academic research into industrial settings. Pharmaceutical companies are increasingly interested in deuterated compounds due to their potential for patent extension and competitive advantage. By leveraging isotopic labeling, drug developers can create proprietary formulations that offer superior performance compared to existing treatments. This trend is expected to drive further innovation in the field of deuterated pharmaceuticals.

Future research directions for 4-PIPERIDINE-D9-CARBOXAMIDE include exploring its applications in targeted therapy and combination drug regimens. The compound's stability and metabolic resistance make it an ideal candidate for use in prodrugs, where it can serve as a carrier molecule that releases active therapeutic agents at specific sites within the body. Additionally, its role as a biomarker in disease diagnosis is being actively investigated, with preliminary results suggesting its utility in detecting early-stage cancers and neurological disorders.

The regulatory landscape for 4-PIPERIDINE-D9-CARBOXAMIDE is also evolving, with increasing acceptance of deuterated drugs by regulatory agencies worldwide. As more data becomes available on their safety and efficacy, it is expected that these compounds will gain wider approval for clinical use. This regulatory progress will further accelerate their adoption in both research and therapeutic settings.

In conclusion, 4-PIPERIDINE-D9-CARBOXAMIDE represents a significant breakthrough in pharmaceutical chemistry, offering unique advantages due to its deuterium-labeled structure. Its applications span from fundamental biochemical research to advanced drug development, making it a versatile tool for scientists and clinicians alike. As our understanding of isotopic labeling continues to grow, we can anticipate even more innovative uses for compounds like 4-PIPERIDINE-D9-CARBOXAMIDE, ultimately leading to better healthcare outcomes for patients worldwide.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)